Literature DB >> 25548157

Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy.

Nicholas L Reyes1, Glen B Banks2, Mark Tsang1, Daciana Margineantu3, Haiwei Gu4, Danijel Djukovic4, Jacky Chan1, Michelle Torres1, H Denny Liggitt1, Dinesh K Hirenallur-S1, David M Hockenbery3, Daniel Raftery5, Brian M Iritani6.   

Abstract

Mammalian skeletal muscle is broadly characterized by the presence of two distinct categories of muscle fibers called type I "red" slow twitch and type II "white" fast twitch, which display marked differences in contraction strength, metabolic strategies, and susceptibility to fatigue. The relative representation of each fiber type can have major influences on susceptibility to obesity, diabetes, and muscular dystrophies. However, the molecular factors controlling fiber type specification remain incompletely defined. In this study, we describe the control of fiber type specification and susceptibility to metabolic disease by folliculin interacting protein-1 (Fnip1). Using Fnip1 null mice, we found that loss of Fnip1 increased the representation of type I fibers characterized by increased myoglobin, slow twitch markers [myosin heavy chain 7 (MyH7), succinate dehydrogenase, troponin I 1, troponin C1, troponin T1], capillary density, and mitochondria number. Cultured Fnip1-null muscle fibers had higher oxidative capacity, and isolated Fnip1-null skeletal muscles were more resistant to postcontraction fatigue relative to WT skeletal muscles. Biochemical analyses revealed increased activation of the metabolic sensor AMP kinase (AMPK), and increased expression of the AMPK-target and transcriptional coactivator PGC1α in Fnip1 null skeletal muscle. Genetic disruption of PGC1α rescued normal levels of type I fiber markers MyH7 and myoglobin in Fnip1-null mice. Remarkably, loss of Fnip1 profoundly mitigated muscle damage in a murine model of Duchenne muscular dystrophy. These results indicate that Fnip1 controls skeletal muscle fiber type specification and warrant further study to determine whether inhibition of Fnip1 has therapeutic potential in muscular dystrophy diseases.

Entities:  

Keywords:  AMPK; BHD; PGC1α; folliculin; mTOR

Mesh:

Substances:

Year:  2014        PMID: 25548157      PMCID: PMC4299192          DOI: 10.1073/pnas.1413021112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism.

Authors:  D Grahame Hardie
Journal:  Proc Nutr Soc       Date:  2010-11-11       Impact factor: 6.297

Review 2.  Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Authors:  Urs T Ruegg
Journal:  Curr Opin Neurol       Date:  2013-10       Impact factor: 5.710

Review 3.  Fiber types in mammalian skeletal muscles.

Authors:  Stefano Schiaffino; Carlo Reggiani
Journal:  Physiol Rev       Date:  2011-10       Impact factor: 37.312

4.  AMPK: a cellular energy sensor primarily regulated by AMP.

Authors:  Graeme J Gowans; D Grahame Hardie
Journal:  Biochem Soc Trans       Date:  2014-02       Impact factor: 5.407

Review 5.  Mitochondrial dysfunction in neuromuscular disorders.

Authors:  Christos D Katsetos; Sirma Koutzaki; Joseph J Melvin
Journal:  Semin Pediatr Neurol       Date:  2013-11-05       Impact factor: 1.636

6.  Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development.

Authors:  Heon Park; Karen Staehling; Mark Tsang; Mark W Appleby; Mary E Brunkow; Daciana Margineantu; David M Hockenbery; Tania Habib; H Denny Liggitt; George Carlson; Brian M Iritani
Journal:  Immunity       Date:  2012-05-17       Impact factor: 31.745

7.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

8.  Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice.

Authors:  Stephanie A Parsons; Benjamin J Wilkins; Orlando F Bueno; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 9.  Hereditary kidney cancer: unique opportunity for disease-based therapy.

Authors:  W Marston Linehan; Peter A Pinto; Gennady Bratslavsky; Elizabeth Pfaffenroth; Maria Merino; Cathy D Vocke; Jorge R Toro; Donald Bottaro; Len Neckers; Laura S Schmidt; Ramaprasad Srinivasan
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

10.  Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene.

Authors:  A P Monaco; R L Neve; C Colletti-Feener; C J Bertelson; D M Kurnit; L M Kunkel
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

View more
  39 in total

1.  Combining NMR and LC/MS Using Backward Variable Elimination: Metabolomics Analysis of Colorectal Cancer, Polyps, and Healthy Controls.

Authors:  Lingli Deng; Haiwei Gu; Jiangjiang Zhu; G A Nagana Gowda; Danijel Djukovic; E Gabriela Chiorean; Daniel Raftery
Journal:  Anal Chem       Date:  2016-08-01       Impact factor: 6.986

Review 2.  Skeletal muscle mitochondrial remodeling in exercise and diseases.

Authors:  Zhenji Gan; Tingting Fu; Daniel P Kelly; Rick B Vega
Journal:  Cell Res       Date:  2018-08-14       Impact factor: 25.617

3.  Polybrominated Diphenyl Ethers and Gut Microbiome Modulate Metabolic Syndrome-Related Aqueous Metabolites in Mice.

Authors:  David K Scoville; Cindy Yanfei Li; Dongfang Wang; Joseph L Dempsey; Daniel Raftery; Sridhar Mani; Haiwei Gu; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2019-05-23       Impact factor: 3.922

4.  miR-208b modulating skeletal muscle development and energy homoeostasis through targeting distinct targets.

Authors:  Liangliang Fu; Heng Wang; Yinlong Liao; Peng Zhou; Yueyuan Xu; Yunxia Zhao; Shengsong Xie; Shuhong Zhao; Xinyun Li
Journal:  RNA Biol       Date:  2020-02-24       Impact factor: 4.652

5.  Muscle-specific deletion of Prkaa1 enhances skeletal muscle lipid accumulation in mice fed a high-fat diet.

Authors:  Weiche Wu; Ziye Xu; Ling Zhang; Jiaqi Liu; Jie Feng; Xinxia Wang; Tizhong Shan; Yizhen Wang
Journal:  J Physiol Biochem       Date:  2017-12-29       Impact factor: 4.158

6.  Chimpanzee super strength and human skeletal muscle evolution.

Authors:  Matthew C O'Neill; Brian R Umberger; Nicholas B Holowka; Susan G Larson; Peter J Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

Review 7.  Control of B lymphocyte development and functions by the mTOR signaling pathways.

Authors:  Terri N Iwata; Julita A Ramírez-Komo; Heon Park; Brian M Iritani
Journal:  Cytokine Growth Factor Rev       Date:  2017-05-22       Impact factor: 7.638

8.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

9.  Globally Optimized Targeted Mass Spectrometry: Reliable Metabolomics Analysis with Broad Coverage.

Authors:  Haiwei Gu; Ping Zhang; Jiangjiang Zhu; Daniel Raftery
Journal:  Anal Chem       Date:  2015-12-02       Impact factor: 6.986

10.  A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.

Authors:  Nicholas P Whitehead; Min Jeong Kim; Kenneth L Bible; Marvin E Adams; Stanley C Froehner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.